Navigation Links
UF scientists to work with German firm in prostate cancer treatment research
Date:6/18/2008

GAINESVILLE, Fla. University of Florida department of urology officials signed an agreement Tuesday to collaborate with the German biopharmaceutical company CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment.

CureVac which specializes in the therapeutic application of messenger RNA, a biomolecule that transfers genetic information from nuclear DNA to cellular protein production machinery is developing a stabilized mRNA-derived vaccine for treatment of prostate cancer.

UF researchers will conduct a phase 1/2 clinical trial of the therapy in patients from the United States with metastatic prostate cancer who no longer respond to hormone therapy. Both institutions hope the initial collaboration will result in a better biologic product to work with in the second phase of the clinical trial.

"The agreement with the University of Florida represents our first step to the U.S. as the world's leading pharmaceutical marketplace with world-class academic institutions for research and development," said Thomas Lander, M.D., managing director and chief medical officer of CureVac.

In what will be the first direct-application trial of its kind in the United States, researchers plan to test molecules that have shown the potential to stimulate an immune response against tumors when injected into the skin, potentially providing an alternative therapy for this form of cancer.

"Several studies support the therapeutic potential of mRNA for the treatment of cancer," said Johannes Vieweg, M.D., a professor and chairman of UF's department of urology who is a member of CureVac's scientific advisory board. "This, however, will be the first clinical trial in the U.S. to use the direct application route by injecting modified mRNA into the skin."

UF urology researchers have treated more than 500 patients using RNA-based dendritic cells, which have been used in vaccines to treat the cancer, but these cells are difficult to manufacture and are often limited in quantity. Researchers hope to discover whether CureVac's technology may be an equivalent or more effective therapy to stimulate tumor response, Vieweg said.

"Our extensive experience and expertise in immunological monitoring and vaccine development are of value to companies such as CureVac, I believe, making us an attractive partner to work with," Vieweg said.

The Prostate Cancer Foundation estimates nearly 200,000 men will be diagnosed with prostate cancer in the United States in 2008. Treatment options generally include surgery or radiation if patients are diagnosed at an early stage. Hormone therapy is often used when cancer has spread beyond the prostate gland.

The proposed clinical trial is expected to begin in 2009. In the first phase of the trial, researchers will seek to define the optimal dose level of the therapy, as well as establish safety and evaluate improvements needed for the regimen. A European clinical trial is also planned.


'/>"/>

Contact: Melissa M. Thompson
thompsmelissa@gmail.com
352-273-5810
University of Florida
Source:Eurekalert

Related medicine news :

1. Scientists from Granada drastically reduce the wait time for new teeth implant
2. Possible link between different forms of epilepsy found by Carnegie Mellon scientists
3. Scientists Discover Protein Involved in Fat Production
4. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
5. QBI neuroscientists make Alzheimers disease advance
6. EPA scientists recognized with prestigious honor
7. 2collab Survey Reveals That Scientists and Researchers are "All Business" With Social Applications
8. Scientists ID Brain Pathway That Stops Seizures
9. Scientists ID Gene Regulating Blood Glucose Levels
10. South African scientists access European research via EMBC agreement
11. Zebrafish enable scientists to study the migration of neurons that enable sexual maturity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... , ... Mediaplanet is proud to announce the launch of ... treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage ... in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today ... intelligent, connected applications, was named the best Sales Team of 2016 as part ... was made today by the Software & Information Industry Association (SIIA), the principal ...
(Date:11/30/2016)... ... , ... "I hate when the mixture of saliva and toothpaste runs down ... from Bridgewater, N.J. "I thought that there had to be a way to prevent ... patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto ...
(Date:11/30/2016)... U.K. (PRWEB) , ... November 30, 2016 , ... ... address the tech functions and stylish design wanted by today’s consumers at an ... Cronovo Co-Founder Darin Philip says the new watch is “a game changer” when ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... 2, 2016 Orthopedic Implants (Including Spinal ... Expected to Gain a Significant Market Share Owing to a ... ... According to a new report by ... Sterile Packaging: Clamshell Product Type Segment Projected to Witness a ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology: